Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Receivables - Accured (2018 - 2020)

Historic Revenue - Other for Marker Therapeutics (MRKR) over the last 1 years, with Q2 2016 value amounting to $1828.0.

  • Marker Therapeutics' Revenue - Other changed N/A to $1828.0 in Q2 2016 from the same period last year, while for Jun 2017 it was $1828.0, marking a year-over-year change of. This contributed to the annual value of $1828.0 for FY2016, which is N/A changed from last year.
  • As of Q2 2016, Marker Therapeutics' Revenue - Other stood at $1828.0.
  • Marker Therapeutics' Receivables - Accured's 5-year high stood at $112200.0 during Q1 2019, with a 5-year trough of $135.0 in Q3 2020.
  • In the last 3 years, Marker Therapeutics' Receivables - Accured had a median value of $56189.0 in 2019 and averaged $53511.6.
  • In the last 5 years, Marker Therapeutics' Receivables - Accured tumbled by 4805.83% in 2019 and then crashed by 9982.72% in 2020.
  • Marker Therapeutics' Receivables - Accured (Quarter) stood at $108177.0 in 2018, then tumbled by 48.06% to $56189.0 in 2019, then crashed by 99.01% to $559.0 in 2020.
  • Its Receivables - Accured was $559.0 in Q4 2020, compared to $135.0 in Q3 2020 and $3440.0 in Q2 2020.